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Abstract
Objective: To study the clinical and biochemical effects of a low starting dose for gold therapy in
rheumatoid arthritis patients with a contact allergy to gold.
Methods: Serum cytokines were assayed before and 24 h after the first injection of gold sodium
thiomalate (GSTM).
Results: Contact allergy to gold was found in 4 of 19 patients. Compared to gold-negative patients
(starting dose: 10 mg GSTM), there was a larger increase in serum TNFalpha (p < 0.05), sTNF-R1
(NS), and IL-1 ra (p < 0.05) in gold-allergic patients.
Conclusions: Cytokines are released in blood by GSTM in RA patients with gold allergy. To
minimize the risk of acute adverse reactions the starting dose of GSTM should be lowered to 5 mg.
Alternatively, patients should be patch-tested before gold therapy; in test-positive cases, 5 mg is
recommended as the first dose.
Introduction
Contact allergy to gold, as diagnosed by patch testing with
gold sodium thiosulfate (GSTS), is very common among
patients with eczematous disease [1–3]. These patients are
allergic also to other monovalent gold salts such as gold
sodium thiomalate (GSTM)[4].
We have previously shown that contact allergy to gold is
frequent also in rheumatoid arthritis (RA) patients[5].
Furthermore, it has been shown that subjects with a con-
tact allergy to gold experience acute reactions, cutaneous
as well as general, if they are exposed parenterally to their
contact allergen[6]. The reactions are accompanied by a
release of plasma cytokines and acute phase reactants dur-
ing the first 24 h after the gold injection[7].
Gold therapy in RA with GSTM is usually started with a
"test dose" of 10 mg to avoid hypersensitivity reactions. In
the present study a starting dose of 5 mg was given to pa-
tients with a gold allergy while test negative patients ob-
tained the higher standard dose; clinical reactions were
registered as well as changes in body temperature and
plasma cytokines.
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Material and methods
Patients, testing, treatment
The study was performed in 19 patients with RA, 4 males
and 15 females, aged 30–75 years, mean age 63.5 years.
They all had RA according to the classification criteria of
ACR[8] with a median duration of 23 ms (range 4 ms to
20 ys). The patients were selected because of a planned
treatment with parenteral gold and informed consent was
obtained. Only one of the patients had previously ob-
tained parenteral gold therapy which, however, had soon
been withdrawn because of lacking effect. At the time of
the study, all patients were on non-steroidal anti-inflam-
matory drugs; in addition, 2 were treated with sulfasala-
zine, 2 with chloroquine, 1 with methotrexate, and 10
with corticosteroids (dosage 3.75–15 mg prednisolone/
day, mean 9.1 mg/day). The study was approved by the
Ethics committee of the Lund University Medical Faculty.
Before gold treatment, the patients were patch tested with
GSTS 0.5, 2.0 and 5.0 w/w %, GSTM 36.0 w/w % (Myoc-
risinR, Rhone Poulenc Rorer), and auranofin 47 w/w %
(RidauraR, SmithKline Beecham), all mixed in petrola-
tum[6]. Patches were applied on the back for 48 h using
Finn ChambersR on ScanporR. Since patch test reactions
to gold salts often are delayed and the early reactions
longlasting[9] the tests were read one week after applica-
tion using criteria for positive patch tests from the Interna-
tional Contact Dermatitis Research Group [10].
Immediately before the first gold treatment, a venous
blood sample was withdrawn, centrifuged and freeze-
stored. Also, the body temperature was measured. The pa-
tients were then given an intramuscular injection of
GSTM. If the outcome of patch tests was positive for a gold
salt the patients obtained a dose of 5 mg; if negative, the
dose was 10 mg. The patients were observed for cutaneous
or other reactions during the following 24 h. At this point,
another blood sample was taken. The body temperature
was registered 10 and 24 h after the injection.
Laboratory studies
Enzyme-linked immunosorbent assay of neutrophil gela-
tinase associated lipocalin (NGAL) and soluble tumour
necrosis factor receptor type 1 (sTNF-R1) was performed
as earlier described[11,12]. Tumour necrosis factor-alpha
(TNF-α) and interleukin-1 receptor antagonist (IL-1 ra)
were measured with ELISA kits (Quantikine™ from R&D
Systems, Minneapolis, USA).
Statistics
Change of plasma cytokines was calculated using the Wil-
coxon rank sum test.
Results
Clinical reactions
The results of patch testing are given in Table 1. A contact
allergy to GSTS was observed in 4 of the 19 patients. Three
of the GSTS-positive patients were allergic also to GSTM
but no positive test reactions could be demonstrated to
auranofin.
With one exception among the 19 patients, there were no
side effects suspected to be caused by GSTM during the
first 24 h after the i.m. injection. Thus, one patient (F 51,
Table 1) with a seronegative RA but patch test positive to
GSTS felt ill 10 h after the 5 mg GSTM injection with ma-
laise, vomiting and tachycardia, and a discrete macular
rash was observed over the abdomen. There was no tem-
perature rise and she was well again at 24 h.
Laboratory results
The body temperature did not change during the first 24
h after the GSTM injection. The mean temperature among
the 19 patients was 37°.1 C immediately before the treat-
ment as well as 10 and 24 h thereafter. Nor was there a
change of body temperature in the 4 patients with a gold
allergy.
The blood cytokine assays, the results of which are pre-
sented in Table 2, showed a statistically significant in-
crease of TNF-alpha and IL-1 ra in the gold-positive
patients after the GSTM injection. No such increase was
seen in the gold-negative patients who, however, had high
baseline values.
Discussion
Contact allergy to gold is common, not only among pa-
tients with eczematous disease[1], but also in certain ref-
erence groups. Thus, Goldermann et al found 6.0 %
positive to GSTS among healthy controls[13], Gruvberger
et al 10.3 % among plastic plant employees[14], Fleming
et al 4.8 % among volunteers in the staff of a dental hos-
pital[15], and Isaksson et al 12.5 % among other plastic
plant employees[16], none of which had any occupation-
Table 1: Positive test reactions in four RA patients one week after 
application of patch tests.
Test substance F 51 F 70 M 71 F 57
GSTS 0.5 % - - (+) -
GSTS 2.0 % ++ ++ + (+)
GSTS 5.0 % ++ ++ +(+) +(+)
GSTM ++ + + -
Auranofin - - - -
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al contact with metallic gold. Test concentrations in these
studies were never higher than 0.5 % which in some cases
may be too low.
Thus, in our case report[17] and prospective study[5] we
found 9 RA patients with contact allergy to gold; 6 of the
9 were patch test negative to GSTS 0.5 % and had been
considered negative if an extended skin testing had not
been performed. This may explain the negative test results
among RA patients observed by Fleming et al[18]. A con-
tributing factor may have been concomitantly given im-
munosuppressant drugs. Another factor may be the lower
frequency of gold dental fillings in the Scottish than in the
Swedish population[19]. A positive correlation between
contact allergy to gold and the presence of dental gold has
been suggested [20–22] and recently ascertained[23].
After gold therapy, only few RA patients have a contact al-
lergy to gold[5,13,24]. Before such treatment, however,
gold allergy is fairly frequent[5]. It was therefore not sur-
prising in the present study to find 4 out of 19 patients
patch test positive to GSTS (Table 1). As mentioned
above, no one was positive to 0.5 %, only to higher con-
centrations. It is possible that the disease proper may im-
ply a partial immunosuppression[25].
Longterm cutaneous side effects are very common during
treatment with gold preparations. Mucocutaneous side ef-
fects were the reason for withdrawing treatment with gold
in 20 % of cases in RA[26]. In the present study, two of the
four gold-positive patients were continued on a series of
GSTM treatment without cutaneous side effects. One of
them (F 57, Table 1) had to stop treatment because of al-
buminuria. The other (F 70) obtained a total of 2840 mg
GSTM during 2 years and her disease went into remission.
The remaining two test-positive patients did not receive
further GSTM courses, one (F 51) because of the acute ad-
verse effects, the other (M 71) because of nephrosclerosis.
Among the 15 test-negative patients all were given courses
of GSTM injections which, however, had to be discontin-
ued in 8 cases because of adverse effects such as albuminu-
ria, haematuria, thrombocytopenia etc but no skin
complaints.
An allergic pathogenesis of "gold dermatitis", the frequent
longterm side effect of chrysotherapy, has been suggested
but was not supported by an early histopathological
study[27]. Nor has this hypothesis been corroborated by
positive allergological tests, e.g. patch tests[13,26]. An im-
munohistochemical and electron microscopic study[28]
as well as an in vitro lymphocyte proliferation study[24],
however, speak in favour of some type of allergic mecha-
nism behind "gold dermatitis". In this latter report it was
also noted that 1/13 RA patients with "gold dermatosis"
was patch test positive to gold salts. She was the only one
to endure an acute, cutaneous and generalized reaction to
the first GSTM dose of 10 mg, i.e. the type of response de-
scribed from our group[29].
On the basis of the present small material, it is impossible
to evaluate the importance of a contact allergy to gold for
the risk of traditional cutaneous ("gold dermatitis") or
generalized side effects. However, the acute reactions dis-
cussed in the present paper may be avoided if the patients
before treatment are properly skin tested and/or the start-
ing dose chosen with care.
Several cytokines are instrumental in the pathogenesis of
the allergic contact dermatitis, in the primarily elicited ec-
zematous reaction as well as in the endogenous flare up
after systemic provocation[30]. TNFalpha, sTNF-R1, and
IL-1 ra are released in blood when GSTM is given by intra-
muscular injection to a subject with contact allergy to
GSTS[7]. The release has been shown to be specific and ac-
tivated only by the proper contact allergen[31]. This spe-
cificity was confirmed in the present work: gold allergen,
when given to gold-positive patients, released the cy-
tokines, not when given to gold-negative patients (Table
2). Obviously, GSTM is not a cytokine releaser by pharma-
cological or toxicological properties which seems to hold
true also for rheumatic patients.
Table 2: Blood cytokines in RA patients allergic and not allergic to gold: mean baseline values and mean percentual change after GSTM 
injection.
TNF-alpha sTNF-R1 IL-1 ra NGAL
Base Increase Base Increase Base Increase Base Increase
Gold neg(n = 15) 6.3 5 4.8 -6 625 0.3 200 12
Gold pos (n = 4) 3.5 60* 1.6 8 326 82* 185 10
Baseline values are given in pg/ml plasma (TNF-alpha, IL-1 ra), ug/1 serum (sTNF R1), and ug/1 plasma (NGAL). * = p < 0.05 compared to gold neg-
ative patients.
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The baseline values of all cytokines were numerically
higher in the gold-negative patients than in the gold-pos-
itive ones (Table 2). There was, however, no statistical dif-
ference for any cytokine, nor any other difference (age,
gender) between the two groups under study. The absence
of a cytokine release among gold-negative patients could
possibly be explained by an earlier release which thus had
been missed by our single blood sampling at 24 h. True,
we have earlier shown that the release of cytokines after
systemic provocation with the contact allergen is obvious
already after 6 h[7]. It was, however, not less after 24 h
and the assay can therefore not be considered false-nega-
tive. With regard to release of sTNF-R1 there was a numer-
ical but statistically not significant increase when
comparing gold-positive and gold-negative patients (Ta-
ble 2) which might be explained by the small patient ma-
terial.
TNF-alpha and other cytokines seem to play a pathogenet-
ic role also in the joint inflammation of RA[32], providing
a rationale for the increasing use of anti-TNF-alpha drugs
in this disease. Not surprisingly, in the present study
blood baseline values of TNF-alpha, sTNF-R1 and IL-1 ra
were fairly high (Table 2). After the systemic gold treat-
ment the cytokines were released to a high degree in pa-
tients with a contact allergy to gold but not in those
negative at patch testing. The difference was statistically
significant for TNF-alpha and IL-1 ra, not for sTNF-R1.
A pathogenetic role played by neutrophilic leukocytes in
the arthritic process has earlier been suggested[33]. How-
ever, no release of the leukocytic protein NGAL was pro-
voked by GSTM (Table 2) which is in accordance with
recent results[34].
The cytokine release was thus demonstrated also in pa-
tients given the very low starting dose of 5 mg GSTM. In
other words: the biochemical reaction is evident in the ab-
sence of clinical side effects. Interestingly, patients with
eczematous disease and gold allergy in many cases experi-
ence acute influenza-like symptoms with fever as well as
muscle and joint aches when given even a small GSTM in-
jection[6]. The absence of such side-effects in the present
study might be due to the antipyretic drugs taken by the
patients.
In the present study, RA patients with a contact allergy to
gold were given a starting dose of GSTM reduced to 5 mg
while the gold-negative patients obtained the regular
starting dose of 10 mg. Only one of the 19 patients had an
acute reaction with malaise and a rash and she was one of
the 4 gold-positive patients. In our previous work[5] two
gold-positive RA patients were given 5 mg GSTM without
problems. Thus, we have given 6 such patients a test dose
of 5 mg GSTM without acute side-effects in 5 of them. We
conclude that 10 mg GSTM is without risk in a gold-nega-
tive patient while 5 mg may be a recommended starting
dose for a gold-positive patient, thereby avoiding acute al-
lergic reactions in most cases.
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